Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMPD1 | P17405 | 3/20 | 0.39 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.33 |
| ▸ | LPAR3 | Q9UBY5 | 5/20 | 0.31 |
| ▸ | LPAR1 | Q92633 | 4/20 | 0.31 |
| ▸ | LPAR2 | Q9HBW0 | 2/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.31 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.31 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.31 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.31 |
| ▸ | LPAR5 | Q9H1C0 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13095377 | 0.98 | SMPD1 (0.40) | SMPD1GRM4LPAR3LPAR1LPAR2 | |
| SCHEMBL6259864 | 0.96 | SMPD1 (0.39) | SMPD1GRM4LPAR3LPAR1LPAR2 | |
| SCHEMBL3030580 | 0.94 | SMPD1 (0.42) | SMPD1GRM4LPAR3LPAR1LPAR2 | |
| SCHEMBL3040690 | 0.92 | SMPD1 (0.43) | SMPD1GRM4LPAR3LPAR1LPAR2 | |
| SCHEMBL6259880 | 0.90 | SMPD1 (0.42) | SMPD1GRM4LPAR3LPAR1LPAR2 | |
| SCHEMBL6259130 | 0.88 | SMPD1 (0.39) | SMPD1LPAR3LPAR1LPAR2CYP3A4 | |
| SCHEMBL13322578 | 0.85 | SMPD1 (0.39) | SMPD1LPAR3LPAR1LPAR2LPAR5 | |
| SCHEMBL3043320 | 0.84 | LPAR3 (0.42) | SMPD1LPAR3LPAR1LPAR2LPAR5 | |
| SCHEMBL6257928 | 0.83 | SMPD1 (0.37) | SMPD1GRM4 | |
| SCHEMBL13095381 | 0.83 | SMPD1 (0.53) | SMPD1GRM4LPAR3LPAR1S1PR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1862444-A2 | Ether compounds, compositions, and uses thereof | Esperion Therapeutics, Inc. (US) | 2007-12-05 | — | — | EP | claimed |
| EP-1849760-A1 | Ether compounds, compositions, and uses thereof | Esperion Therapeutics Inc. (US) | 2007-10-31 | — | — | EP | claimed |
| US-7192940-B2 | Ether compounds | ESPERION THERAPEUTICS, INC. (US) | 2007-03-20 | — | — | US | claimed |
| US-20050004082-A1 | Therapy for cardiovascular, metabolism and cholesterol disorders | ESPERION THERAPEUTICS, INC. | 2005-01-06 | — | — | US | claimed |
| US-20030149094-A1 | Compositions comprising ether compounds and pharmaceutical uses therefor | ESPERION THERAPEUTICS, INC. | 2003-08-07 | — | — | US | claimed |
| US-20030065195-A1 | Ether compounds | ESPERION THERAPEUTICS, INC. | 2003-04-03 | — | — | US | claimed |
| US-6459003-B1 | ETHER COMPOUNDS FOR TREATMENT OF CARDIOVASCULAR DISORDERS, METABOLISM DISORDERS AND CHOLESTEROL DISORDERS | ESPERION THERAPEUTICS, INC. | 2002-10-01 | — | — | US | claimed |
| US-20100256209-A1 | COMPOSITIONS COMPRISING ETHER COMPOUNDS AND PHARMACEUTICAL USES THEREFOR | ESPERION THERAPEUTICS, INC. | 2010-10-07 | — | — | US | disclosed |
| US-7709515-B2 | Compositions comprising ether compounds and pharmaceutical uses therefor | ESPERION THERAPEUTICS, INC. (US) | 2010-05-04 | — | — | US | disclosed |
| EP-1204626-B1 | ETHER COMPOUNDS, COMPOSITIONS, AND USES THEREOF | ESPERION THERAPEUTICS INC (US) | 2008-01-16 | — | — | EP | disclosed |
| EP-1862444-A2 | Ether compounds, compositions, and uses thereof | Esperion Therapeutics, Inc. (US) | 2007-12-05 | — | — | EP | disclosed |
| EP-1849760-A1 | Ether compounds, compositions, and uses thereof | Esperion Therapeutics Inc. (US) | 2007-10-31 | — | — | EP | disclosed |
| US-20070203212-A1 | METHOD OF TREATING OSTEOARTHRITIS | WARNER-LAMBERT COMPANY (US) | 2007-08-30 | — | — | US | disclosed |
| WO-2004017952-A1 | METHOD OF TREATING OSTEOARTHRITIS | WARNER-LAMBERT COMPANY LLC (US) | 2004-03-04 | — | — | WO | disclosed |
| US-6646170-B2 | Hydroxy derivatives; cardiovascular diseases, dyslipidemias, dysproteinemias, glucose metabolism disorders | ESPERION THERAPEUTICS, INC. | 2003-11-11 | — | — | US | disclosed |
| US-20030149094-A1 | Compositions comprising ether compounds and pharmaceutical uses therefor | ESPERION THERAPEUTICS, INC. | 2003-08-07 | — | — | US | disclosed |
| US-20030125559-A1 | Methods for synthesizing ether compounds and intermediates therefor | ESPERION THERAPEUTICS, INC. | 2003-07-03 | — | — | US | disclosed |
| US-6506799-B1 | Treating or preventing a cardiovascular disease in a patient, comprising administering to a patient in need of such treatment or prevention a therapeutically effective amount of 6-(6-hydroxy-5,5-dimethylhexyloxy)-2,2-dimethyl-hexan-1-ol and | ESPERION THERAPEUTICS, INC. | 2003-01-14 | — | — | US | disclosed |
| US-6459003-B1 | ETHER COMPOUNDS FOR TREATMENT OF CARDIOVASCULAR DISORDERS, METABOLISM DISORDERS AND CHOLESTEROL DISORDERS | ESPERION THERAPEUTICS, INC. | 2002-10-01 | — | — | US | disclosed |
| US-6410802-B1 | ETHERIFICATION IN PRESENCE OF BASE | ESPERION THERAPEUTICS, INC. | 2002-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256209-A1 | COMPOSITIONS COMPRISING ETHER COMPOUNDS AND PHARMACEUTICAL USES THEREFOR | GPR119, ECHS1, PNLIP | SMPD1 694/4885GRM4 1366/4885LPAR3 695/4885 |
| US-20070203212-A1 | METHOD OF TREATING OSTEOARTHRITIS | SYVN1, MMP13, TNF | SMPD1 4165/4885GRM4 1895/4885LPAR3 200/4885 |
| US-20030125559-A1 | Methods for synthesizing ether compounds and intermediates therefor | ECHS1, GPR119, PC | SMPD1 973/4885GRM4 1610/4885LPAR3 832/4885 |
| US-20030065195-A1 | Ether compounds | GPR119, PPARG, PNLIP | SMPD1 860/4885GRM4 966/4885LPAR3 708/4885 |
| US-20050004082-A1 | Therapy for cardiovascular, metabolism and cholesterol disorders | GPR119, NR1H2, PC | SMPD1 532/4885GRM4 871/4885LPAR3 555/4885 |
| US-20030149094-A1 | Compositions comprising ether compounds and pharmaceutical uses therefor | GPR119, ECHS1, PNLIP | SMPD1 694/4885GRM4 1366/4885LPAR3 695/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.